DeFi Technologies' Subsidiary Reflexivity Research Announces Strategic Partnership with Beluga
Reflexivity Research, a subsidiary of DeFi Technologies, has partnered with Beluga, a leading platform that makes crypto simple and easy to understand.
The partnership will drive joint business development, expand distribution reach, and offer co-branded research and strategic advisory services to token foundations and projects across the digital asset space.
TORONTO, June 10, 2025 /CNW/ - DeFi Technologies Inc. (the " Company" or " DeFi Technologies") (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B), a financial technology company bridging the gap between traditional capital markets and decentralized finance ("DeFi"), is pleased to announce that its wholly owned subsidiary, Reflexivity Research LLC (" Reflexivity Research")., a leading crypto research firm, has entered into a strategic partnership with Beluga, a leading platform that makes crypto simple and easy to understand. This collaboration is designed to accelerate joint business development, enhance distribution reach, and deliver comprehensive research services across both retail and institutional segments.
The partnership formalizes a co-marketing and referral agreement between Reflexivity Research and Beluga, leveraging each firm's strengths to expand their respective customer bases. Under the collaboration, the Reflexivity Research and Beluga will:
Expand research distribution through joint content and cross-platform promotion
Strengthen their referral networks and client acquisition efforts
Explore co-branded research and strategic advisory for token foundations
"Reflexivity Research is one of the most respected names in on-chain research and analysis," said Sonny Singh, CEO of Beluga. "By combining our storytelling and distribution capabilities with their insights, we can help bring high-quality crypto research to a much broader audience."
"We are excited to work closely with the Beluga team to further strengthen Reflexivity Research's position as the premier research provider in the digital asset space," said Olivier Roussy Newton, CEO of DeFi Technologies. "By aligning with a high-impact marketing partner like Beluga, we're expanding both our institutional and retail presence while deepening our value proposition to protocols, foundations, and investors."
This collaboration marks another milestone in DeFi Technologies' commitment to building a robust digital asset ecosystem through strategic subsidiaries and partnerships.
About Beluga
Beluga is a leading crypto intelligence platform designed to help everyday users and investors navigate the digital asset economy with confidence. Known as the "NerdWallet for crypto," Beluga simplifies the complex world of blockchain, DeFi, and digital assets through unbiased product comparisons, curated market insights, educational content, and real-time data. Beluga empowers millions of users to discover the best wallets, exchanges, and tools across Web3. Beluga's Top 50 List has become the leading site to learn about the best tokens that are launching. Whether you're new to crypto or managing a growing portfolio, Beluga is your trusted guide for smarter decisions in the decentralized world. Beluga's investors include some of the biggest names in crypto and fintech. For more information please visit https://heybeluga.com/
About DeFi Technologies
DeFi Technologies Inc. (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B) is a financial technology company bridging the gap between traditional capital markets and decentralized finance (" DeFi"). As the first Nasdaq-listed digital asset manager of its kind, DeFi Technologies offers equity investors diversified exposure to the broader decentralized economy through its integrated and scalable business model. This includes Valour, which offers access to over sixty-five of the world's most innovative digital assets via regulated ETPs; Stillman Digital, a digital asset prime brokerage focused on institutional-grade execution and custody; Reflexivity Research, which provides leading research into the digital asset space; Neuronomics, which develops quantitative trading strategies and infrastructure; and DeFi Alpha, the Company's internal arbitrage and trading business line. With deep expertise across capital markets and emerging technologies, DeFi Technologies is building the institutional gateway to the future of finance. Follow DeFi Technologies on LinkedIn and X/Twitter, and for more details, visit https://defi.tech/
DeFi Technologies Subsidiaries
About Valour
Valour Inc. and Valour Digital Securities Limited (together, " Valour") issues exchange traded products (" ETPs") that enable retail and institutional investors to access digital assets in a simple and secure way via their traditional bank account. Valour is part of the asset management business line of DeFi Technologies. For more information about Valour, to subscribe, or to receive updates, visit valour.com.
About Stillman Digital
Stillman Digital is a leading digital asset liquidity provider that offers limitless liquidity solutions for businesses, focusing on industry-leading trade execution, settlement, and technology. For more information, please visit https://www.stillmandigital.com
About Reflexivity Research
Reflexivity Research LLC is a leading research firm specializing in the creation of high-quality, in-depth research reports for the bitcoin and digital asset industry, empowering investors with valuable insights. For more information please visit https://www.reflexivityresearch.com/
About Neuronomics AG
Neuronomics AG is a Swiss asset management firm specializing in AI-powered quantitative trading strategies. By integrating artificial intelligence, computational neuroscience and quantitative finance, Neuronomics delivers cutting-edge solutions that drive superior risk-adjusted performance in financial markets. For more information please visit https://www.neuronomics.com/
Analyst Coverage of DeFi Technologies
A full list of DeFi Technologies analyst coverage can be found here: https://defi.tech/investor-relations#research.
For inquiries from institutional investors, funds, or family offices, please contact: ir@defi.tech
Cautionary note regarding forward-looking information:
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to the collaboration between Beluga and Reflexivity Research; the regulatory environment with respect to the growth and adoption of decentralized finance; the pursuit by the Company and its subsidiaries of business opportunities; and the merits or potential returns of any such opportunities. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Such risks, uncertainties and other factors include, but is not limited the acceptance of Valour exchange traded products by exchanges; growth and development of decentralised finance and digital asset sector; rules and regulations with respect to decentralised finance and digital assets; fluctuation in digital asset prices; general business, economic, competitive, political and social uncertainties. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
11 minutes ago
- Cision Canada
Two Hands Corporation Announces Retention of New Executives to Further its Business Development in the Food Services Sector
TORONTO, June 12, 2025 /CNW/ - Two Hands Corporation (" Two Hands" or the " Company") (CSE: TWOH.X) (OTC: TWOH) is pleased to announce it has engaged renowned culinary expert Chef Einat Admony and accomplished executive Vanessa Fayzulin to lead the revitalization of its food service division. Together, they bring deep expertise in food retail, culinary innovation, and distribution services. In response to the rapid expansion of the gig economy, Two Hands is launching a dynamic new venture in collaboration with Chef Admony and Ms. Fayzulin. The venture will be operated under the proposed new corporate subsidiary name ChefXperience (" ChefXperience"). Vanessa Fayzulin is the visionary behind the venture and will serve as Founder and Chief Executive Officer of ChefXperience. Chef Admony recently joined as Co-Founder of this new initiative. This innovative mobile platform is designed to expand the Company's service offerings and capitalize on evolving labor trends. Two Hands is proud to be in a leadership position in innovating this platform offering to the U.S. market. This initiative caters to the growing importance of the "gig" economy in the U.S. labor market. Under the proposed terms of the partnership, subject to final legal documentation, Two Hands will retain a 51% ownership stake in ChefXperience, while the remaining 49% will remain in the hands of key executives and third-party investors. As of 2023, more than 41 million Americans were engaged in freelance or gig-based work 1 including approximately 7 million working as food delivery contractors 2. ChefXperience is uniquely positioned to tap into this expanding labor market by enabling skilled home cooks to generate income through personalized, in-home meal preparation services. The launch of this platform in the U.S. by Two Hands, through ChefXperience, follows the successful rollout of similar business models internationally. ChefXperience management is actively exploring strategic partnerships with these and other international players as potential avenues for collaboration, market expansion, and future acquisitions, positioning the Company for long-term global growth. Chef Admony and Ms. Fayzulin— who are collaborating together to launch this project - are excited to bring this innovative concept to life. Emil Assentato, CEO of Two Hands Corporation, brings a wealth of experience in financial services and technology to the company. Prior to his role at Two Hands, Mr. Assentato served as Chairman and CEO of Tradition North America, a subsidiary of Compagnie Financière Tradition (SWX: CFT), which is publicly listed on the Swiss Stock Exchange. Mr. Assentato was also the original founder and CEO of Nukkleus Inc., a financial technology firm listed on NASDAQ, where he was instrumental in driving the company's early growth. Craig Marshak, Director of the Company who currently advises on board strategy and development, previously served as Head of the Nomura Global Technology Merchant Banking Fund. During his tenure, he helped lead investments in several high-profile ventures, including cybersecurity company CyberArk (NASDAQ: CYBR) and which was later acquired by eBay. Mr. Marshak has also played a strategic role in advising Nukkleus and brings deep expertise in M&A and global tech investments. He is currently the Co-Chairman of Bannix Acquisition Corp., a SPAC. About Chef Einat Admony Chef Admony is a celebrated New York-based chef and culinary entrepreneur. She has recently gained widespread recognition as a featured chef on the CookUnity platform, where she has amassed a significant following of home chefs. A 2022 James Beard semifinalist for Best Chef: New York State, Chef Admony has been featured on the Food Network, CBS, NBC, and more. She is also the founder of several acclaimed restaurants across the U.S., including Balaboosta in New York City. About Vanessa Fayzulin Vanessa Fayzulin is a seasoned business executive and entrepreneur with a strong background in media, finance, and digital content. During her six years at Bloomberg, she worked in Creative Video Operations, overseeing media management and publishing workflows. Her prior experience includes producing and editing at TheStreet as well as Univision. Ms. Fayzulin originally conceived and commenced work on the ChefXperience project back in 2023. Ms. Fayzulin studied Journalism at the University of Texas at Austin. In connection with the launch of the ChefXperience platform, Two Hands will contribute US$56,000 to the newly formed subsidiary, which will primarily be used for app development and startup expenses. Two Hands expects to provide further funding of up to US$2 million to ChefXperience over the next 12 months. The Company also expects to appoint Ms. Admony to the Board of Two Hands. The launch of the ChefXperience platform constitutes a Change of Business (as such term is defined in the policies of the Canadian Securities Exchange (the " CSE")) and is subject to the approval of the CSE and the shareholders of the Company. About Two Hands Corporation: Two Hands has been active in the Food Retail and Distribution Service Industry 9 SIC Code 7389) for several years, focusing on the Consumer Non-Cyclical sector. The Company is dedicated to providing quality products and services to meet the needs of its customers. Neither the CSE nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Information This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. Forward looking statements in this news release include statements regarding the anticipated launch of ChefXperience, expected services to be provided by Ms. Admony and Ms. Fayzulin, the anticipated ownership of ChefXperience, the business proposed to be carried out under the ChefXperience brand, the anticipated financing of ChefXperience by Two Hands and the appointment of Ms. Admony to the Board of the Company. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors that could materially affect such forward-looking information are described under the heading "Risk Factors" in the Company's final long-form prospectus dated April 21, 2022, that is available on the Company's profile on SEDAR+ at The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements' best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. For further information, please visit
Cision Canada
an hour ago
- Cision Canada
HYCROFT ANNOUNCES PRICING AND UPSIZING OF PUBLIC OFFERING OF UNITS
WINNEMUCCA, Nev., June 12, 2025 /CNW/ -- Hycroft Mining Holding Corporation (Nasdaq: HYMC) ("Hycroft" or the "Company") is pleased to announce the pricing of an underwritten offering of 12,500,000 units of the Company (the "Units") at a public offering price of $3.50 per Unit (the " Offering"). Each Unit consists of one share of common stock of the Company and one-half of one common stock purchase warrant (each whole warrant, a " Warrant"). Each Warrant will be exercisable to purchase one share of common stock of the Company at a price of $4.20 per share, exercisable for a period of 36 months. The shares of common stock and Warrants will be issued separately but can only be purchased together in the Offering. The gross proceeds from the Offering are expected to be approximately $43,750,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In addition, Hycroft has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 units, shares of common stock and/or Warrants, at the underwriters' discretion. The Offering is expected to close on June 13, 2025, subject to customary closing conditions. Hycroft intends to use the net proceeds from the Offering for further exploration, working capital and general corporate purposes. BMO Capital Markets and Paradigm Capital Inc. are acting as joint book-running managers for the Offering. SCP Resource Finance LP is acting as a capital markets advisor to the Company. The Offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-279292) that was filed by the Company with the U.S. Securities and Exchange Commission (the " SEC"), as amended. A preliminary prospectus supplement relating to and describing the terms of the Offering has been filed with the SEC and is available on the SEC's website at Copies of the preliminary prospectus supplement and accompanying prospectus, as well as copies of the final prospectus supplement, once available, may be obtained upon request by contacting BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, or by email at [email protected]. This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Hycroft Mining Holding Corporation Hycroft Mining Holding Corporation is a US-based gold and silver company developing the Hycroft Mine, among the world's largest precious metals deposits located in northern Nevada, a Tier-One mining jurisdiction. After a long history of oxide heap leaching operations, the Company is focused on completing the technical studies to transition the Hycroft Mine into the next phase of commercial operations for processing the sulfide ore. In addition, the Company is engaged in a robust exploration drill program to further expand the newly discovered high-grade dominant silver systems and unlock the full potential of this worldclass asset, including oxide leaching potential at Manganese. For further information, please contact: [email protected] Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking statements" within the meaning of Section 27A of the United States Securities Act of 1933, as amended, Section 21E of the United States Securities Exchange Act of 1934, as amended, or the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included herein and public statements by our officers or representatives, that address activities, events or developments that our management expects or anticipates will or may occur in the future, are forward- looking statements, including but not limited to such things as future business strategy, plans and goals, competitive strengths and expansion and growth of our business. The words "estimate", "plan", "anticipate", "expect", "intend", "believe" "target", "budget", "may", "can", "will", "would", "could", "should", "seeks", or "scheduled to" and similar words or expressions, or negatives of these terms or other variations of these terms or comparable language or any discussion of strategy or intention identify forward-looking statements. Forward-looking statements address activities, events, or developments that the Company expects or anticipates will or may occur in the future and are based on current expectations and assumptions. Forward-looking statements in this news release relate to, among other things, the closing of the Offering and the timing thereof, the intended use of proceeds of the Offering and the strategic vision and objectives for the Company and expectations regarding exploration potential. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to changes in our operations at the Hycroft Mine, including risks associated with the cessation of mining operations at the Hycroft Mine; uncertainties concerning estimates of mineral resources; risks related to a lack of a completed feasibility study; risks related to our ability to re-establish commercially feasible mining operations; industry related risks, including fluctuations in the price of gold and silver; the commercial success of, and risks related to, our exploration and development activities; uncertainties and risks related to our reliance on contractors and consultants; and the availability and cost of equipment, supplies, energy, or reagents. The occurrence of one or more of the events or circumstances described alone or in combination with other events or circumstances may have a material adverse effect on the Company's business, cash flows, financial condition, and results of operations. Please see our "Risk Factors" outlined in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports we have filed with the SEC for more information about these and other risks. You are cautioned against attributing undue certainty to forward-looking statements. Although we have attempted to identify important factors that could cause actual results to differ materially from those described in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Although these forward-looking statements were based on assumptions that the Company believed were reasonable when made, you are cautioned that forward-looking statements are not guarantees of future performance and that actual results, performance, or achievements may differ materially from those made in or suggested by the forward-looking statements in this news release. In addition, even if our results, performance, or achievements are consistent with the forward-looking statements contained in this news release, those results, performance or achievements may not be indicative of results, performance or achievements in subsequent periods. Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements made in this news release speak only as of the date of those statements. Readers cannot be assured that the Offering will be completed on the terms described above, or at all. We undertake no obligation to update those statements or publicly announce the results of any revisions to any of those statements to reflect future events or developments except as required by applicable law. All forward-looking statements contained in this news release are expressly qualified by the foregoing cautionary statements.
Cision Canada
an hour ago
- Cision Canada
After Major Oncology Conference, All Eyes Turn to Industry Innovation
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /CNW/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors, there have been several oncology innovators and healthcare providers with recent developments to pay attention to, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Tempest Therapeutics, Inc. (NASDAQ: TPST), Citius Oncology, Inc. (NASDAQ: CTOR), Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), and Cardinal Health (NYSE: CAH). As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual cases by 2030 and a staggering 75% increase by 2050. According to analysts at ResearchAndMarkets, the global oncology market is projected to reach US$866.1 billion by 2034, rising at a 10.8% CAGR, while Vision Research Reports projects the global oncology market to surpass US$903.81 billion by 2034, at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) just announced a major leadership transition that could mark a pivotal chapter in its clinical and corporate trajectory. The company has appointed Jared Kelly as Chief Executive Officer and member of the Board, a move that brings in a seasoned biotech dealmaker known for high-value M&A and immuno-oncology strategy. Kelly most recently played a central role (as General Counsel) in the $2 billion sale of Ambrx Biopharma to Johnson & Johnson. Prior to that, he advised numerous biotech firms on licensing and acquisitions during his tenure at leading law firms Kirkland & Ellis LLP and Lowenstein Sandler LLP. In joining Oncolytics, he inherits one of the most intriguing immunotherapy agents and pipelines in clinical oncology: pelareorep, a virus-based agent with broad synergy potential in solid and hematologic tumors. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear priority: advancing pelareorep toward late-stage inflection points with a capital-efficient and partnership-aware strategy. The asset currently holds FDA Fast Track designation in both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare distinction that reinforces its regulatory momentum. In trials to date, pelareorep has consistently demonstrated immune activation, synergy with chemotherapies and checkpoint inhibitors, and unusually strong response rates across difficult-to-treat cancers. In metastatic pancreatic cancer (mPDAC), pelareorep has delivered over 60% objective response rates in tumor evaluable patients across Phase 1 and 2 studies—more than double those observed in historical controls — and, separately, two-year survival rates 4-6 times those observed in control patients or in prior studies. In HR+/HER2- metastatic breast cancer, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed meaningful survival benefit. And in anal cancer, early data from a phase 2 cohort combining pelareorep with a checkpoint inhibitor showed partial or complete responses in nearly half of evaluable patients—far exceeding historical norms for monotherapy. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." To align incentives with long-term shareholder value, Kelly's compensation package includes equity and milestone-based awards tied to future strategic transactions and financings. The structure reflects Oncolytics' intention to drive both clinical and corporate progress without overextending its cap table—while remaining attractive to potential collaborators. As multiple programs advance within the GOBLET study—including pancreatic and anal cancer cohorts backed by regulatory support and third-party funding— Oncolytics appears poised to benefit from a combination of scientific traction, capital flexibility, and strategic leadership. In other recent industry developments and happenings in the market include: Tempest Therapeutics, Inc. (NASDAQ: TPST), has secured Orphan Drug Designation from the European Medicines Agency (EMA) for amezalpat, its lead small molecule immunotherapy for hepatocellular carcinoma (HCC). The news builds on prior FDA Fast Track and Orphan Drug status granted earlier this year. "We're incredibly pleased to receive Orphan Drug Designation from the EMA, building on the momentum of regulatory support we've already received from the FDA," said Stephen Brady, president and chief executive officer of Tempest Therapeutics. "These designations reflect the significant unmet need in liver cancer and reinforce our belief in the potential of amezalpat to make a meaningful difference for patients and families affected by this devastating disease." In a randomized Phase 1b/2 study, amezalpat added to standard-of-care therapy extended median overall survival by six months and showed preserved benefit across key subpopulations. The compound is designed to inhibit PPAR⍺ activity and enhance immune response in the HCC tumor microenvironment. Citius Oncology, Inc. (NASDAQ: CTOR), the oncology division of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), has signed a U.S. distribution agreement with Cardinal Health (NYSE: CAH) as it prepares to launch LYMPHIR, its recently FDA -approved treatment for relapsed or refractory cutaneous T-cell lymphoma (CTCL). "This agreement marks a key step forward in our launch readiness efforts," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. " Cardinal Health's proven distribution capabilities will help ensure LYMPHIR reaches healthcare providers and patients efficiently and reliably, as we work to build a robust commercial distribution network." LYMPHIR is a targeted recombinant fusion protein that binds IL-2 receptors and delivers diphtheria toxin fragments to malignant cells. The drug is indicated for adult patients with Stage I–III CTCL after at least one prior systemic therapy and was approved by the FDA in August 2024. Under the agreement, Cardinal Health will serve as an authorized distributor of record and provide specialty pharmaceutical distribution services across the U.S. market. This collaboration is designed to ensure patients and providers have reliable access to LYMPHIR as demand grows. Citius estimates the addressable market for this indication exceeds $400 million and remains underserved by current treatment options. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
